iTeos Therapeutics, Inc. (ITOS)
iTeos Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Watertown, MA, US. The stock last traded at $10.15, up 0.20% on the session, giving a market capitalisation of $448.7M. On trailing twelve-month figures it carries a trailing P/E of -3.89, a net margin of 0.0%. Its beta of 1.49 implies it has historically moved more than the broad market.
iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC). Established in 2011, iTeos Therapeutics, Inc. is based in Watertown, Massachusetts.
iTeos Therapeutics, Inc. is most often compared with the following Healthcare names: